Abstract

Acute myeloid leukaemia (AML) is a heterogeneous, most common type of acute leukaemia that involves mutation in haematopoietic and progenitors stem cells (HPSCs) leading to uncontrolled division, self-renewal and differentiation. Though it was untreatable about a half century ago, AML is now considered to be treatable in up to 40% of adults and those who are at or under 60 years of age. For the post-induction treatment, the mutation testing and cytogenetics are still an important prognostic tool. The AML treatment remains unchanged for almost three decades, although the field is advanced with the discovery of new drugs and deep understanding of the disease biology. Still, many people are relapsing and are dying eventually from the disease. This review discusses the broader aspects of AML, reflecting some of the most important and productive areas of research on the subject and was conducted using thoroughly searching databases, including Health Research and Development Information network Plus (HERDIN Plus), google scholar and PubMed to critically analysesthe recent advances, available treatments and future prospectives of AML.

Keywords: AML; Pathogenesis; Treatment; Relapse